Back to Search
Start Over
Exceptional Response to Pembrolizumab and Trastuzumab in a Heavily Pretreated Patient With HER2-Positive TMB-H and MSI-H Metastatic Breast Cancer
- Source :
- JCO Precision Oncology. :904-909
- Publication Year :
- 2021
- Publisher :
- American Society of Clinical Oncology (ASCO), 2021.
- Subjects :
- Cancer Research
Receptor, ErbB-2
business.industry
Breast Neoplasms
Exceptional Response
Pembrolizumab
Middle Aged
Trastuzumab
Antibodies, Monoclonal, Humanized
medicine.disease
Metastatic breast cancer
Antineoplastic Agents, Immunological
Oncology
Mutation
medicine
Cancer research
Humans
Female
Microsatellite Instability
Neoplasm Metastasis
business
medicine.drug
Subjects
Details
- ISSN :
- 24734284
- Database :
- OpenAIRE
- Journal :
- JCO Precision Oncology
- Accession number :
- edsair.doi.dedup.....3e9f57acae2758d94b761febccbbd2cb
- Full Text :
- https://doi.org/10.1200/po.20.00361